S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Sigilon Therapeutics Stock Forecast, Price & News

+0.03 (+1.38%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
97,721 shs
Average Volume
109,480 shs
Market Capitalization
$71.08 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sigilon Therapeutics logo

About Sigilon Therapeutics

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Sigilon Therapeutics (NASDAQ:SGTX) PT Lowered to $7.00
December 23, 2021 |  americanbankingnews.com
Sigilon Therapeutics to lay off 40 employees
December 14, 2021 |  finance.yahoo.com
Sigilon Therapeutics Announces Strategic Reprioritization
December 13, 2021 |  finance.yahoo.com
Sigilon Therapeutics, Inc. Common Stock (SGTX)
December 6, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.37 million


Pretax Margin




Free Float
Market Cap
$71.08 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.94 out of 5 stars

Medical Sector

677th out of 1,417 stocks

Analyst Opinion: 3.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Sigilon Therapeutics (NASDAQ:SGTX) Frequently Asked Questions

Is Sigilon Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Sigilon Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View analyst ratings for Sigilon Therapeutics
or view top-rated stocks.

When is Sigilon Therapeutics' next earnings date?

Sigilon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Sigilon Therapeutics

How were Sigilon Therapeutics' earnings last quarter?

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.03. The company had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million.
View Sigilon Therapeutics' earnings history

What price target have analysts set for SGTX?

3 analysts have issued twelve-month target prices for Sigilon Therapeutics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Sigilon Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 240.9% from the stock's current price.
View analysts' price targets for Sigilon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sigilon Therapeutics' key executives?

Sigilon Therapeutics' management team includes the following people:
  • Dr. Rogerio Vivaldi Coelho M.D., MBA, Pres, CEO & Director (Age 57, Pay $802.37k)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72, Pay $101.89k)
  • Dr. Daniel G. Anderson Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 51, Pay $100.63k)
  • Dr. Omid Veiseh Ph.D., Co-Founder
  • Dr. José Oberholzer M.D., Co-Founder
  • Dr. Arturo Vegas Ph.D., Co-Founder
  • Mr. Philip Ashton-Rickardt Ph.D., Chief Scientific Officer
  • Mr. Robert Windsor Jr., J.D., VP & Head of Investor Relations
  • Mr. Matthew Kowalsky J.D., Chief Legal Officer (Age 49)
  • Ms. Vanya Sagar, Chief HR Officer (Age 46)

When did Sigilon Therapeutics IPO?

(SGTX) raised $101 million in an initial public offering on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.

What is Sigilon Therapeutics' stock symbol?

Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX."

How do I buy shares of Sigilon Therapeutics?

Shares of SGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sigilon Therapeutics' stock price today?

One share of SGTX stock can currently be purchased for approximately $2.20.

How much money does Sigilon Therapeutics make?

Sigilon Therapeutics has a market capitalization of $71.08 million and generates $13.37 million in revenue each year.

How many employees does Sigilon Therapeutics have?

Sigilon Therapeutics employs 99 workers across the globe.

What is Sigilon Therapeutics' official website?

The official website for Sigilon Therapeutics is sigilon.com.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.